Brean sees FDA rejecting Rockwell's Triferic

Brean is out with a decisively negative note on Rockwell Medical (RMTI), calling Triferic "far from terrific."

Analyst Jonathan Aschoff doesn't mince words in initiating the shares at Sell: "We believe the FDA will reject Triferic due to poor clinical trial design and questionable efficacy."

"CRUISE had a questionable design that we view as unlikely to result in approval," Aschoff says, elaborating. "More than 80% of the patients in all CRUISE arms did not complete the 48-week treatment period, making the primary endpoint evaluation period highly variable."

Price target is $4, representing downside of more than 70% from Monday's close.

For more on the CRUISE trials, see here.

RMTI -7% premarket

From other sites
Comments (12)
  • condormaen
    , contributor
    Comment (1) | Send Message
    well - lets see ...
    17 Dec 2013, 08:41 AM Reply Like
    , contributor
    Comment (1) | Send Message
    I wonder if his information this time is any better than the call he made on DNDN?? He had to retract that one.
    17 Dec 2013, 08:42 AM Reply Like
  • villashaka
    , contributor
    Comments (45) | Send Message
    It's taken them three months to question Cruise 2 results ? Please, I will wait for the FDA to decide, not these clowns as they have provided zero in the way of hard data or scientific methodology.
    17 Dec 2013, 10:18 AM Reply Like
  • lawman13
    , contributor
    Comments (4) | Send Message
    When the hell is Rockwell going to comment?
    17 Dec 2013, 11:29 AM Reply Like
  • Blue22
    , contributor
    Comments (449) | Send Message
    Enough of this crap! Show investors the evidence before making such statements. Nothing I have read points to any negatives in trials so far, quite the reverse.
    17 Dec 2013, 12:00 PM Reply Like
  • Justhinking
    , contributor
    Comments (9) | Send Message
    Here's why you should not believe this Aschoff non sense;


    Excerpt: In 2003 – back when journalists still occasionally investigated stories, rather than parroting whatever hedge funds and Wall Street analysts whispered in their ears – The Wall Street Journal won a Pulitzer Prize for a story that nailed Jonathan Aschoff for being a fraud.
    According to the Journal, Aschoff often impersonated doctors in order to acquire inside information on the status of drug trials underway at his target companies. A certain Dr. Cunningham, who worked at a cancer center in Dallas, told the Journal that he initially believed that Aschoff was a doctor. But he discovered that he was dealing with a fraud when he mentioned to Aschoff that an experimental treatment had caused some reduction of the “lymphadenopathy.”
    “What’s that?” asked Aschoff. He didn’t have a clue, even though “lymphadenopathy” is a common medical term. It means, “swollen lymph nodes.”
    17 Dec 2013, 12:18 PM Reply Like
  • Stephen Tips
    , contributor
    Comments (638) | Send Message


    VERY interesting link.


    I also found it unusual when this happened December 5, 2013, regarding Auxilium Pharmaceuticals’’ (AUXL) PDUFA for Xiaflex:


    Bart Classen, analyst for Summer Street was reputed to be "skeptical that the FDA will approve [Xiaflex] for Peyronies disease without an Ad Com."


    That same day, December 5, Moody's revised AUXL to Negative (from Stable).


    The very next day, December 6, 2013, the FDA approved Xiaflex.


    Where is the SEC?
    17 Dec 2013, 01:06 PM Reply Like
  • teavecilla
    , contributor
    Comments (4) | Send Message
    When an analyst predicted jcp target price at 1.00 i bought more shares at the 52 week low and made money in 2 wks. Rmti has run up and they want to scare individual investors to sell so they can buy. I go against what they recommend and usually make my money. I am a hemodialysis RN worked for both fmc and davita. Total renal care TRC was at 2$/ sh when davita took over - the rest was history. I am long on rmti . Triferic is not the only product in their line. I had been trading since 1990's and learned the devious ways of paid analyst. They PLAY the market and the investors
    18 Dec 2013, 01:00 AM Reply Like
  • Doyee51986
    , contributor
    Comments (328) | Send Message
    I completely disagree with Brean Capitals Sell Rating and 4 dollar price target of Rockwell Medical and their conclusion that their signature upcoming product won't be accepted by the FDA. So does the street, who has a 25 dollar price target and notes - "The pivotal CRUISE design was put together with FDA and achieved the primary endpoint on efficacy was statistically significant in both trials. In addition the safety data was great. Every single accusation Yocum (the former employee) made has been proven false by clinical facts. The Dose worked. Patients were safe. The analyst who initiated on RMTI did not even speak to RMTI prior to putting out his negative research report,"


    Ignoring the authors lack of credibility, the 230% upside on the Street's price target on the company that has patented soluble iron concentrate made today a great buying opportunity. Watch this video and you'll see why this is such a game changer.


    Disclosure: I've worked in the dialysis industry as a biomedical engineer for 5 years and am long RMTI and FMS. I got lucky and bought more shares at the 9.65 when the low was 9.51, and the stock is now 10.80, hopefully heading on up to 25 .
    17 Dec 2013, 08:36 PM Reply Like
  • Doyee51986
    , contributor
    Comments (328) | Send Message
    Website is: (add www.)
    17 Dec 2013, 10:20 PM Reply Like
  • teavecilla
    , contributor
    Comments (4) | Send Message
    I am an individual investor and been playing the market since 1990- lost money in the bubble burst. My first equity was cvx , lmt and aol. I am a registered nurse with focus on hemodialysis began my career in 1983. I have followed the market since and been with ameritrade initially then moved to fidelitty investments
    18 Dec 2013, 12:59 AM Reply Like
  • pimsgate
    , contributor
    Comment (1) | Send Message
    Jonathan Aschoff is incorrect about RMTI in a big way !
    7 Jan 2014, 07:38 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs